

ADVENTRX PHARMACEUTICALS INC

Form 8-K

April 25, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **April 25, 2005**

**ADVENTRX Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**001-32157**  
(Commission File Number)

**84-1318182**  
(IRS Employer Identification No.)

**6725 Mesa Ridge Road, Suite 100  
San Diego, California 92121**  
(Address of principal executive offices) (Zip Code)

**(858) 552-0866**  
(Company's telephone number, including area code)

---

Item 8.01. Other Events.

On April 25, 2005, the Company announced that it received FDA clearance for its CoFactor Phase III pivotal trial in metastatic colorectal cancer.

The press release issued by the Company on April 25, 2005 with respect to this matter is included with this report as an exhibit.

Item 9.01. Financial Statements and Exhibits.

(99) ©The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

By: /s/ Carrie E. Carlander

\_\_\_\_\_  
**Name:** Carrie E. Carlander

**Title:** Chief Financial Officer, Vice President, Finance, and  
Treasurer

April 25, 2005

---

EXHIBIT INDEX

Exhibit Description

99.1 Press Release of the Company dated April 25, 2005.

---